The impact of osimertinib' line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming strategies for resistance.
暂无分享,去创建一个
H. Nechushtan | L. Roisman | N. Peled | L. Soussan-Gutman | A. Dvir | R. Gillis | J. Dudnik | W. Kian | I. Goldstein | Vered Fuchs | L. Daniel | R. Grinberg | Roni Gillis
[1] R. Rosell,et al. Mechanisms of resistance to osimertinib , 2020, Journal of thoracic disease.
[2] M. Ahn,et al. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] E. Giovannetti,et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer , 2019, British Journal of Cancer.
[4] H. Hou,et al. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis , 2019, BMC Cancer.
[5] V. Papadimitrakopoulou,et al. Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer , 2019, Clinical Cancer Research.
[6] M. Mino‐Kenudson,et al. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Sharyn I. Katz,et al. Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer , 2019, JAMA oncology.
[8] Young Hak Kim,et al. Successful Treatment with Osimertinib and Chemotherapy in a Non-Small Cell Lung Cancer Patient with EGFR Mutation and Meningeal Carcinomatosis. , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[9] L. Roisman,et al. The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell‐Free DNA in Advanced Lung Cancer , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[10] Paul Baas,et al. Liquid Biopsy for Advanced Non‐Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[11] B. Besse,et al. Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI? , 2018, Nature Reviews Clinical Oncology.
[12] Yong He,et al. Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib. , 2018, Lung cancer.
[13] Yunpeng Liu,et al. Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients , 2018, Clinical Cancer Research.
[14] Ying Cheng,et al. Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.
[15] S. Mortimer,et al. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients , 2017, Clinical Cancer Research.
[16] Yi-long Wu,et al. Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First‐ and Third‐Generation EGFR TKIs and Shifts Allelic Configuration at Resistance , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[17] H. Do,et al. Combination Osimertinib and Gefitinib in C797S and T790M EGFR‐Mutated Non–Small Cell Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[18] Thomas John,et al. Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] D. Gandara,et al. Subclonal Therapy by Two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR-Mutated Lung Cancer. , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[20] M. Varella‐Garcia,et al. Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in EGFR-Mutant Non-Small Cell Lung Cancer. , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[21] C. Azzoli,et al. MET amplification (amp) as a resistance mechanism to osimertinib. , 2017 .
[22] ping wang,et al. Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer , 2017, Oncotarget.
[23] S. Kobayashi,et al. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes. , 2017, Lung cancer.
[24] Yasushi Okuno,et al. Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer , 2017, Nature Communications.
[25] Chia-Chi Lin,et al. Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Shuhang Wang,et al. EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance. , 2017, Cancer letters.
[27] Shuhang Wang,et al. Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors , 2016, Frontiers of Medicine.
[28] Matthew Grist,et al. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity , 2016, Clinical Cancer Research.
[29] Ash A. Alizadeh,et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients , 2016, Nature Communications.
[30] B. Kermani,et al. Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA , 2015, PloS one.
[31] S. Fujita,et al. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer , 2015, Cancer Chemotherapy and Pharmacology.
[32] P. Jänne,et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. , 2015, The New England journal of medicine.
[33] M. Denis,et al. EGFR T790M resistance mutation in non small-cell lung carcinoma. , 2015, Clinica chimica acta; international journal of clinical chemistry.
[34] G. Getz,et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer , 2015, Nature Communications.